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SUMMARY
Menin displays the unique ability to either promote oncogenic function in the hematopoietic lineage or
suppress tumorigenesis in the endocrine lineage; however, its molecular mechanism of action has not
been defined. We demonstrate here that these discordant functions are unified by menin’s ability to serve
as a molecular adaptor that physically links the MLL (mixed-lineage leukemia) histone methyltransferase
with LEDGF (lens epithelium-derived growth factor), a chromatin-associated protein previously implicated
in leukemia, autoimmunity, and HIV-1 pathogenesis. LEDGF is required for both MLL-dependent transcrip-
tion and leukemic transformation. Conversely, a subset of menin mutations in multiple endocrine neoplasia
type 1 patients abrogate interaction with LEDGF while preserving MLL interaction but nevertheless compro-
miseMLL/menin-dependent functions. Thus, LEDGF critically associates withMLL andmenin at the nexus of
transcriptional pathways that are recurrently targeted in diverse diseases.INTRODUCTION
Cancer results from genetic and epigenetic perturbations that
cause the unbalanced actions of oncoproteins and tumor sup-
pressors. The menin tumor suppressor is implicated in cancer
pathogenesis and transcriptional regulationasan integral compo-
nent of theMLL (mixed-lineage leukemia) histone methyltransfer-
ase (HMT) complex, which promotes specific trimethylation of
lysine 4 on histone H3, an epigenetic mark associated with
transcriptionally active chromatin (Hughes et al., 2004; Milne
et al., 2002; Nakamura et al., 2002; Yokoyama et al., 2004). Menin
is a product of theMEN1 gene, whose loss of function causes the
human cancer syndrome known as multiple endocrine neoplasia
type 1 (MEN1) (Chandrasekharappa et al., 1997). It is also impli-
cated in the dynamic regulation of pancreatic b cell proliferation
in response to normal physiologic demands during pregnancy
whose failure may promote gestational diabetes (Karnik et al.,
2007). Thesenormal andpathologic roles inendocrinecells reflect
specific requirements for the MLL/menin HMT complex to main-36 Cancer Cell 14, 36–46, July 2008 ª2008 Elsevier Inc.tain expression of the CDKN1B and CDKN2C genes, which en-
code the cyclin-dependent kinase inhibitors (CDKIs) p27KIP1 and
p18Ink4c, respectively (Karnik et al., 2005; Milne et al., 2005). Their
compromised expression followingmutation or deletion ofMEN1
leads to hyperproliferation of endocrine lineage cells (Bertolino
et al., 2003; Franklin et al., 1998; Crabtree et al., 2001). Many mu-
tations of menin in endocrine tumors abrogate its ability to asso-
ciate with the MLL HMT complex (Hughes et al., 2004); however,
the specific molecular function of menin is currently unknown.
Transcriptional regulation of HOX genes is also exquisitely de-
pendent on MLL, which is required to establish the embryonic
body plan during development (Yu et al., 1995) and to promote
progenitor expansion and stem cell self-renewal in the hemato-
poietic lineage (Jude et al., 2007; McMahon et al., 2007). In a
subset of acute leukemias, chromosomal aberrations generate
chimeric MLL oncoproteins that cause constitutive expression
of HOX genes, a key feature of MLL leukemia pathogenesis
(Daser and Rabbitts, 2004; Hess, 2004). In contrast to its tumor
suppressor role in MEN1 tumorigenesis, menin serves as anSIGNIFICANCE
Menin is a tumor suppressor whose loss of function causes the human cancer syndrome known as multiple endocrine neo-
plasia type 1. Conversely, menin serves as an essential oncogenic cofactor for MLL (mixed-lineage leukemia) oncoproteins
in leukemic transformation. These discordant functions are attributed in part to tissue-specific differences in critical MLL
target genes; however, the molecular role of menin in these contrasting oncogenic settings remains undefined. We demon-
strate here that menin serves as a molecular adaptor that tethers the MLL histone methyltransferase and its oncogenic
counterparts to LEDGF (lens epithelium-derived growth factor), a transcriptional coactivator previously implicated in
cancer, autoimmunity, and HIV proviral integration. A requirement for LEDGF in MLL/menin transcriptional and oncogenic
actions places it at the center of a key epigenetic pathway in cancer pathogenesis.
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Menin Tethers MLL Proteins to LEDGF in OncogenesisFigure 1. LEDGF and NUP98-LEDGF Associate with the MLL/Menin Histone Methyltransferase Complex
(A) Silver stain image of an SDS-PAGE analysis shows the presence of LEDGF in the purifiedMLL-ENL/menin immunoprecipitate. FLAG-taggedMLL-ENL ((f)ME)
and HA-tagged menin (menin(H)) were transiently expressed in large-scale culture of 293T cells. A nuclear extract was prepared from the cells and subjected to
immunopurification using anti-FLAG antibody. Protein bands from SDS-PAGE analysis were analyzed by mass spectrometry and identified as indicated by
arrows. The band at 52 kDa is a nonspecific (nsp) product that was also observed in the control immunoprecipitate of a nuclear extract from nontransduced cells
(not shown). Protein standards are shown on the left.
(B) Reciprocal immunoprecipitations (IPs) of the MLL-ENL/menin complex. (f)ME or a mutant ((f)MEd) lacking the high-affinity menin-binding motif were
transiently expressed in 293T cells with (+) or without () HA-tagged menin. Nuclear extracts from the transfected cells were subjected to IP with anti-FLAG
or anti-HA antibodies followed by immunoblotting with anti-FLAG, anti-HA, and anti-LEDGF (p75) antibodies.
(C) MLL or MLL-p300 was transiently expressed with (+) or without () HA-tagged menin in 293T cells and subjected to IP with anti-HA antibody followed by
immunoblotting with anti-MLLN, anti-HA, and anti-LEDGF antibodies.
(D) To detect endogenousMLL/menin/LEDGF association, nuclear extract of REH cells was subjected to IP with anti-menin antibody followed by immunoblotting
with anti-MLLC, anti-menin, anti-LEDGF, and anti-actin antibodies. Anti-Drosophila Myb (DmMyb) antibody was used as a negative control.
(E) Schematic representations of the NUP98-LEDGF mutants are shown with a summary of their binding properties with MLL/menin on the right. The identified
minimum MLL/menin-binding domain (MmBD; residues 335–460) is indicated.
(F) His-Express-Myc-tagged NUP98-LEDGF proteins were expressed in 293T cells and subjected to IP with anti-Myc antibody followed by immunoblotting with
anti-Express epitope and anti-menin antibodies.essential cofactor for MLL oncoproteins to sustain HOX gene
misexpression and maintain leukemic transformation (Caslini
et al., 2007; Chen et al., 2006; Yokoyama et al., 2005). Thus, me-
nin has the unusual ability to either promote oncogenic function
in the hematopoietic lineage or suppress tumorigenesis in the
endocrine lineage. These discordant functions are attributed to
tissue-specific differences in critical target genes that encode
oncogenic versus tumor suppressor proteins in hematopoietic
versus endocrine cells, respectively. However, a unifying molec-
ular role for menin underlying transcriptional regulation by nor-
mal and oncogenic MLL proteins has not been defined.
Here we demonstrate that menin tethers MLL with the p75 iso-
form of LEDGF (lens epithelium-derived growth factor, also
called DFS70/p75/PSIP1), a chromatin-associated protein that
is also targeted in various diseases including cancer (Ahujaet al., 2000; Daugaard et al., 2007; Huang et al., 2007), auto-
immunity (Ganapathy and Casiano, 2004), and AIDS (Ciuffi and
Bushman, 2006), thereby providing a crucial molecular link
with chromatin for an epigenetic complex at the center of multi-
ple pathologic processes.
RESULTS
Wild-Type and Oncogenic MLL/Menin Protein
Complexes Specifically Associate with LEDGF
Menin is essential for MLL-dependent transcriptional regulation
and leukemic transformation (Caslini et al., 2007; Chen et al.,
2006; Yokoyama et al., 2005); however, its molecular mecha-
nism of action has not been defined. We hypothesized that
menin might further recruit an unknown factor to the MLL/meninCancer Cell 14, 36–46, July 2008 ª2008 Elsevier Inc. 37
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Menin Tethers MLL Proteins to LEDGF in OncogenesisFigure 2. MLL Proteins Colocalize with LEDGF on Chromatin of Cancer-Associated Genes
(A) Chromatin immunoprecipitation (ChIP) was performed on ML-2 cells using anti-MLLN, anti-menin, and anti-LEDGF antibodies. MLL-AF6, menin, and LEDGF
occupancy was specifically observed at the HOXA7 and HOXA9 loci, but not on the MEIS1 and GAPDH loci. Negative and positive controls consisted of no
antibody and anti-histone H3 antibody, respectively.
(B) ChIP followed by quantitative PCR was performed on ML-2 and U937 cells using anti-MLLN, anti-menin, and anti-LEDGF antibodies. Values are expressed
relative to the maximum value (arbitrarily set at 100%) in each group, with error bars representing standard deviations for triplicate PCR analyses.complex. Since stably associated factors of MLL have been ex-
tensively characterized (Dou et al., 2005; Yokoyama et al., 2004),
we inferred that potential novel factors might associate more
weakly. Thus, the MLL-ENL/menin complex was biochemically
purified by one-step affinity purification from cells transiently ex-
pressing high levels of the respective proteins to minimize the
loss of weakly associated proteins during the purification proce-
dure. In the purified materials, we identified a 75 kDa nuclear
protein termed LEDGF (Figure 1A) previously implicated in tran-
scriptional coactivation (Ge et al., 1998) and lentiviral integration
(Ciuffi and Bushman, 2006).
Specific association of LEDGF with the MLL-ENL/menin
complex was confirmed by reciprocal immunoprecipitation (IP)
experiments using anti-FLAG or anti-HA antibodies to pull down
MLL-ENL or menin, respectively, which showed that endogenous
LEDGF consistently coprecipitated with transiently expressed
menin andMLL-ENL (Figure 1B). However, expression ofmenin or
MLL-ENL alone did not result in coimmunoprecipitation of LEDGF
at a detectable level. Consistentwith these observations, amutant
MLL-ENL (MEd) that lacks the high-affinity menin-binding motif
(hMBM) and therefore does not interact with menin efficiently
(Yokoyama et al., 2005) failed to coprecipitate with endogenous
LEDGF despite the presence of abundant menin (Figure 1B).
These data demonstrate that LEDGF associates conjointly with
MLL-ENL and menin, but not with either protein separately.
LEDGFalso coprecipitatedwithmenin in associationwith tran-
siently expressed wild-type MLL and other MLL fusion proteins
(Figure 1C; see also Figure S1A available online). At a very low
level, LEDGF was detected in the endogenous MLL/menin com-
plex in REH cells as well (Figure 1D). Furthermore, the NUP98-
LEDGF fusion protein created by chromosomal translocation in
acute leukemia (Ahuja et al., 2000) also coprecipitated with the
MLL/menin complex, suggesting a possible pathogenic associa-
tion. Interaction was dependent on the HIV-1 integrase-binding
domain (IBD) (Cherepanov et al., 2004) as revealed by deletion38 Cancer Cell 14, 36–46, July 2008 ª2008 Elsevier Inc.mutagenesis (Figures 1E and 1F), consistent with the inability of
a naturally occurring isoform of LEDGF (p52) that lacks the IBD
to coimmunoprecipitate with MLL/menin (Figure S1B). Thus,
the p75 isoform of LEDGF is a specific cofactor for both
wild-type and oncogenic MLL/menin protein complexes.
LEDGF Colocalizes with MLL Proteins and Menin
on Crucial Target Genes
Chromatin immunoprecipitation (ChIP) analyses demonstrated
that LEDGF colocalizes with MLL/menin complexes at target
sites withinHOXA,MEIS1, andCDKI genes (Figure 2; Figure S2),
all previously linked with MLL/menin pathologies (Ayton and
Cleary, 2003; Karnik et al., 2005; Milne et al., 2005; Wong
et al., 2007). This was the case in U937 cells, which lack MLL
gene rearrangement and express only wild-type MLL (Dreyling
et al., 1996; Guenther et al., 2005), and in ML-2 cells, which
exclusively express MLL-AF6 in the absence of wild-type MLL
(Tanabe et al., 1996; Yokoyama et al., 2005). The occupancy of
MLL-AF6 or wild-typeMLL throughout theHOXA locus and other
target loci extensively overlapped with menin and LEDGF
(Figure 2B). Thus, LEDGF forms stable complexes with MLL (or
MLL oncoproteins) in vivo on genes implicated to critically medi-
ate MLL/menin-associated biology and disease.
LEDGF Is Required for Initiation of Leukemic
Transformation by MLL Oncoproteins
A structure/function analysis of MLL-ENL revealed that deletions
spanning MLL residues 112–153 completely abolished LEDGF
binding while preserving menin association (Figures 3A and
3B; Figure S3). This defined an evolutionally conserved region
within the amino-terminal portion of MLL as a specific LEDGF-
binding domain (LBD) distinct from the hMBM.
The MLL-ENL deletion mutants were evaluated for oncogenic
activity using a transformation assay that reads out the ability of
MLL fusion genes to induce enhanced self-renewal of myeloid
Cancer Cell
Menin Tethers MLL Proteins to LEDGF in OncogenesisFigure 3. MLL Oncoproteins Associate with LEDGF to Initiate Myeloid Transformation
(A) Schematic structure of the MLL-ENL oncoprotein. The amino acid sequence of MLL encompassing the LEDGF-binding domain (LBD; residues 109–153
denoted by red box) is aligned with that of fugu MLL. Arrow indicates the phenylalanine residue converted to alanine.
(B) Various mutants of (f)ME were transiently expressed with (+) or without () HA-tagged menin in 293T cells and subjected to IP with anti-HA antibody followed
by immunoblotting with anti-FLAG, anti-HA, and anti-LEDGF antibodies.
(C) Experimental scheme for the myeloid progenitor transformation assay. The time point at which Hoxa9 expression was measured (end of 1st plating) is
indicated.
(D) Colony-forming units (cfu) per 104 plated cells are shown for each round of plating. Error bars represent standard deviations of three independent experiments.
(E) Relative expression levels of Hoxa9 are shown for 1st-round colonies. Expression levels are normalized to b-actin and expressed relative to the ME value
(arbitrarily set at 100%). Error bars represent standard deviations of triplicate PCR analyses.
(F) Subnuclear localizations of MLL fusion proteins in HeLa cells are shown as a merged image of signals for FITC (MLL) and DAPI (DNA). Scale bar = 10 mm.progenitors in vitro compared with control cells, which rapidly
exhaust their clonogenic potentials. All deletion mutants unable
to associate with LEDGF were also unable to transform myeloid
progenitors (Figures 3C and 3D). Moreover, a single amino acid
substitution within the LBD that converted an evolutionally con-
served phenylalanine to alanine (F129A) completely abolished
LEDGF binding and myeloid transformation. The F129A mutant
was also transcriptionally incapable of maintaining Hoxa9 ex-
pression in transduced myeloid progenitors (Figure 3E) despite
efficient expression and localization in nuclear bodies (Figure 3F).
Thus, specific association with LEDGF is essential for misregula-
tion of Hoxa9 expression and transformation of myeloid progen-
itors by the MLL oncoprotein.
Menin Is an Adaptor that Tethers MLL Oncoproteins
with LEDGF in Transformed Myeloid Progenitors
LEDGF contains a highly conserved motif (PWWP) that is struc-
turally related to the so-called ‘‘royal family’’ of domains present
in a wide variety of chromatin-associated proteins and impli-
cated in recognition of modified nucleosomes (Maurer-Stroh
et al., 2003). The PWWP domain of LEDGF is necessary to asso-ciate with chromatinized DNA and target HIV-1 genome integra-
tion to transcriptionally active sites (Botbol et al., 2008; Shun
et al., 2007). We hypothesized, therefore, that menin’s role is to
tether MLL proteins with LEDGF as an adaptor, which in turn
promotes association of the complex with transcriptionally
active chromatin through its PWWP domain.
To test this hypothesis, MLL oncoproteins were engineered
to circumvent menin by replacing the hMBM with the PWWP
domain of LEDGF. The resultant modified MLL-ENL (pME) was
no longer capable of stably associating with menin and LEDGF
(Figures 4A and 4B) but nevertheless strongly upregulated
Hoxa9 expression and efficiently transformed myeloid progeni-
tors (Figures 4A and 4C). Consistent with these observations,
pME function was not compromised by F129A mutation of the
LBD, which otherwise abrogates noncovalent LEDGF interac-
tion. Fusion with PWWP, however, did not bypass the require-
ment for theMLL fusion partner moiety inmyeloid transformation
by pME or a similarly engineered MLL-AF10 (Figures 4A and 4B).
ChIP analysis of pME-transformed cells showed that pME occu-
pied the Hoxa9 locus in the absence of menin and LEDGF
(Figure 4E). Mutation of an evolutionally conserved tryptophanCancer Cell 14, 36–46, July 2008 ª2008 Elsevier Inc. 39
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Menin Tethers MLL Proteins to LEDGF in OncogenesisFigure 4. Menin Tethers LEDGF with MLL Oncoproteins
(A) Schematic structures of menin, MLL-ENL, and LEDGF are shown at the top, with sites of intermolecular interactions indicated by arrows. Binding properties
and transforming abilities are summarized to the right of the respective MLL-ENL constructs. The numbers of 3rd-round cfu in myeloid progenitor assays are
shown at right, with error bars representing the standard deviations of three independent experiments.
(B) Variousmutants of pMEwere transiently expressedwith (+) or without () HA-taggedmenin in 293T cells and subjected to IPwith anti-HA antibody followed by
immunoblotting with anti-MLLN, anti-HA, and anti-LEDGF antibodies. Upper panel shows immunoblot of the nuclear extracts (NE) to determine protein inputs.
Mutants lacking the high-affinity menin-binding motif failed to coimmunoprecipitate with menin and LEDGF.
(C) Relative expression levels are shown for Hoxa9 in 1st-round colonies. Expression levels are normalized to b-actin and expressed relative to the ME value
(arbitrarily set at 100%). Error bars represent standard deviations of triplicate PCR analyses.
(D) Subnuclear localization of the pME mutants in HeLa cells is shown as a merged image of signals for FITC (MLL) and DAPI (DNA). Scale bar = 10 mm.
(E) ChIP analysis of ME- or pME-transformedmyeloid progenitors was performed using the antibodies indicated at the top. Amplicons upstream of theHoxa9 and
b-actin genes were analyzed.
(F) Survival curves are shown for mice transplanted with the indicated transduced cells. The numbers of mice analyzed (n) are indicated.
(G) Expression of ME and pME proteins in immortalized cells (ICs) and leukemic cells (LCs) from bone marrow (BM) and spleen (SP) was analyzed by immuno-
blotting with anti-MLLN and anti-SIN3A (control) antibodies.
(H) Morphology is shown for normal bone marrow (WT, left panel) and pME leukemic blasts (pME, right panel) following May-Grunwald/Giemsa staining of
cytospin preparations. Scale bar = 15 mm.40 Cancer Cell 14, 36–46, July 2008 ª2008 Elsevier Inc.
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Menin Tethers MLL Proteins to LEDGF in OncogenesisFigure 5. LEDGF Is Necessary for Mainte-
nance of MLL Leukemic Transformation
(A) Experimental scheme for conditional inactiva-
tion of Men1 in MLL-transformed cells. The time
points at which cfu or gene expression was
measured are indicated.
(B) Relative cfu for cells transformed byME or pME
in the absence (vector) or presence (Cre-ER) of
Men1 inactivation (vector controls are arbitrarily
set at 100%). Error bars represent standard devia-
tions of three independent analyses.
(C) Morphologies for representative colonies from
the experiment in (B). Scale bar = 150 mm.
(D) Western blot showing expression of pME, me-
nin, and SIN3A proteins after Men1 inactivation.
(E) Relative expression levels of Hoxa9 are shown
for 1st-round colonies after Cre-ER transduction.
Expression levels were normalized to b-actin and
expressed relative to the vector control values
(arbitrarily set at 100%). Error bars represent
standard deviations of triplicate PCR analyses.
(F) Experimental scheme for conditional inactiva-
tion of Ledgf by shRNA-mediated knockdown.
The time points at which cfu or gene expression
was measured are indicated.
(G) The relative cfu activity of ME- or pME-trans-
formed cells is shown with (sh-Ledgf#1 and
sh-Ledgf#2) or without (vector) Ledgf knockdown
(the vector controls are arbitrarily set at 100%).
Error bars represent standard deviations of three
independent analyses.
(H) Relative expression levels of Hoxa9 and Ledgf
are shown for 1st-round colonies after shRNA vec-
tor transduction. Expression levels are normalized
to b-actin and expressed relative to the vector
control values (arbitrarily set at 100%). Error bars
represent standard deviations of triplicate PCR
analyses.to alanine (W21A) in the PWWP motif abolished both Hoxa9 up-
regulation and myeloid transformation, confirming a critical role
of the PWWP domain in pME function (Figures 4A, 4C, and 4D).
Transplantation of pME-transformed cells into congenic recip-
ients induced acute leukemias with latencies and penetrance
similar to those of ME-transplanted mice (Figures 4F and 4G).
In both cohorts, blast cells with morphologic features character-
istic of acute monocytic leukemia massively infiltrated the
spleen, liver, and bone marrow (Figure 4H; Figure S4), and
primary leukemia cells expressing pME were transplantable to
secondary recipients, which developed leukemia with short
latencies (Figures 4F and 4G). Thus, pME induces leukemia
in vivo despite its inability to associate with menin.
A conditional knockout approachwas employed to further con-
firm that menin is dispensable for leukemic transformation by
pME. Myeloid progenitors harvested from Men1 floxed mice
were transformed by ME or pME and subsequently transduced
with Cre-ER (Cre recombinase fused with estrogen receptor),
whichwasconditionally activated in thepresence of 4-hydroxyta-
moxifen (4-OHT) to inactivate the Men1 gene (Figure 5A). While
ME-transformed cells lost their clonogenicity and displayed pre-
dominantly differentiated colonymorphologies afterMen1 inacti-vation aspreviously reported (Yokoyamaet al., 2005), pME-trans-
formed cells retained their transformed phenotype (Figures 5B
and 5C) and maintained high-level Hoxa9 expression in the ab-
sence of menin (Figures 5D and 5E). Thus, covalent fusion of the
PWWP domain of LEDGF to MLL oncoproteins fully bypasses
the requirement formenin inMLL-mediated leukemic transforma-
tion, indicating that the sole molecular requirement for menin as
an oncogenic cofactor in MLL-associated leukemogenesis is to
tether the PWWP domain of LEDGF to the MLL oncoprotein.
Sustained LEDGF Expression Is Required
for Maintenance of Leukemic Transformation
by MLL Oncoproteins
To assess whether LEDGF must be continuously present for
maintenance of MLL-dependent transformation, its expression
was knocked down in ME- and pME-transformed progenitors
using shRNA techniques (Figure 5F). Efficient (>80%) knock-
down of Ledgf expression obtained by two different shRNAs
(Figure 5H) markedly reduced the clonogenic potential of
ME-transformed cells, whereas pME-transformed cells were
unaffected (Figure 5G). Furthermore, Ledgf knockdown im-
paired Hoxa9 expression in ME-transformed cells, but not inCancer Cell 14, 36–46, July 2008 ª2008 Elsevier Inc. 41
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Menin Tethers MLL Proteins to LEDGF in OncogenesisFigure 6. Menin Functionally Interacts with LEDGF
(A) Schematic structures of menin and its mutants. The abilities of each protein to associate with MLL or LEDGF and to rescue MLL-dependent transcription are
summarized on the right. * indicates impaired association as opposed to complete loss of association. ND, not determined.
(B) Various HA-taggedmenin proteins were transiently expressed with (+) or without () (f)ME in 293T cells and subjected to IP with anti-HA antibody followed by
immunoblotting with anti-FLAG, anti-HA, and anti-LEDGF antibodies.
(C) Experimental scheme for rescue ofMen1 knockdown by wild-type or mutant menin proteins. The time points at which cfu or gene expression was measured
are indicated.
(D) Western blot analysis showing expression of menin mutants in ME-transformed cells detected by anti-HA and anti-MLLN antibodies, respectively.
(E) Relative cfu for ME-transformed cells transducedwith variousmeninmutants with (+) or without ()Men1 knockdown (vector control is arbitrarily set at 100%).
Error bars represent standard deviations of three independent analyses.
(F) Relative expression levels of Hoxa9 and Men1 for 1st-round colonies after Men1 knockdown. Expression levels are normalized to Gapdh and expressed
relative to the ME/vector value (arbitrarily set at 100%). Error bars represent standard deviations of triplicate PCR analyses. p values for differences compared
to wild-type menin rescue were determined by unpaired t test. *p < 0.0005; **p < 0.005.pME-transformed cells (Figure 5H). Thus, LEDGF is required to
maintain aberrant Hox gene expression and transformation
induced by MLL oncoproteins.
Implication of LEDGF in Menin Tumor Suppression
To investigate the role of LEDGF in MEN1 tumorigenesis, menin
proteins harboring point mutations found in MEN1 patients were
analyzed for their abilities to associate with MLL proteins and
LEDGF. Several menin mutants (H138D, A242V, and T344R)
displayed no or markedly reduced interactions with MLL (Figures
6A and 6B), consistent with their previously demonstrated inability
to coimmunoprecipitate with HMT activity (Hughes et al., 2004).
Theyalso failed toassociatewithLEDGF,compatiblewithour fore-
going results (Figure 1B) indicating that LEDGF interacts conjointly
withMLL/menin. Othermeninmutants (P12L and L22R), however,
retained competence to coimmunoprecipitate with MLL but were
nevertheless unable to associatewith LEDGF (Figures 6A and 6B).42 Cancer Cell 14, 36–46, July 2008 ª2008 Elsevier Inc.The latter mutants were assessed for their potential to rescue
loss of menin function following shRNA knockdown of endoge-
nous murine Men1 expression in ME-transformed cells (Fig-
ure 6C). In contrast to transduced wild-type menin, which pre-
vented loss of clonogenicity caused by Men1 knockdown, the
P12L and L22R mutants failed to maintain myeloid transforma-
tion (Figures 6D and 6E). They were also unable to optimally
maintain Hoxa9 expression following inactivation of Men1 in
ME-transformed cells compared with wild-type menin-trans-
duced cells (Figure 6F), consistent with a compromised ability
of L22R to maintain CDKI transcription in menin-deficient murine
embryonic fibroblasts (Milne et al., 2005). Therefore, a subset of
menin mutations in MEN1 tumors specifically abrogate LEDGF
interaction while preserving MLL interaction but nevertheless
compromise MLL-dependent functions. These data support
a role for LEDGF in MEN1 tumor suppression as well as MLL-
associated leukemogenesis.
Cancer Cell
Menin Tethers MLL Proteins to LEDGF in OncogenesisDISCUSSION
Our studies establish LEDGF as a crucial cofactor required for
both the oncogenic and tumor suppressor functions of MLL/me-
nin complexes. LEDGF interacts conjointly with MLL and menin
on the chromatin of cancer-associated genes to mediate MLL-
dependent transcription pathways (Figure 7). In this context, me-
nin serves as an adaptor to linkMLLwith LEDGF. A subset ofme-
nin mutations in MEN1 tumors is particularly informative, as they
abrogate interactions with LEDGF, but not MLL, yet compromise
MLL/menin activity. Genetic evidence that MLL functions with
LEDGF in its normal developmental role to regulate HOX gene
expression during establishment of the embryonic body plan is
suggested by the phenotypic overlaps of Mll- and Ledgf-defi-
cient mice, which both display skeletal malformations represen-
tative of anterior and posterior homeotic transformations
(Sutherland et al., 2006; Yu et al., 1995). Thus, LEDGF is an es-
sential component of theMLL/menin HMT complex in the setting
of its normal and pathologic activities.
LEDGF has previously been implicated in various transcrip-
tional processes and cellular functions. Originally discovered
based on its cofractionation with the general transcriptional co-
activator PC4, LEDGF reportedly associates with transcriptional
activators and components of the basal transcriptional machin-
ery including RNA pol II subunits (Ge et al., 1998) and contributes
to the transcriptional response following environmental stress
(Shinohara et al., 2002). Coincidently, menin is also a regulator
of stress-induced response in fruit flies, which transcriptionally
upregulate expression of various heat-shock proteins following
stressful stimuli (Papaconstantinou et al., 2005). Menin has
been reported to coimmunoprecipitate with RNA pol II (Hughes
et al., 2004), raising the possibility that it links MLL with
LEDGF/p75 in higher-order complexes of dynamic composition
to regulate specific stages of transcription.
In addition to its transcriptional role, LEDGF is important for
lentiviral integration (Ciuffi et al., 2005; Llano et al., 2006; Shun
Figure 7. Model for the Role of LEDGF in the
Normal and Neoplastic Functions of the
MLL/Menin HMT Complex
Top: specific association with LEDGF is required
for transcriptional contributions by the MLL/menin
HMT complex at its chromatin sites of action.
Bottom: similarly, the constitutive transcriptional
properties of MLL chimeric oncoproteins in com-
plex with menin are also dependent on association
with LEDGF, whichmay provide amolecular target
for therapeutic intervention.
et al., 2007). LEDGF is the dominant
binding partner for HIV-1 integrase in hu-
man cells (Cherepanov et al., 2003) and
tethers it to host chromosomes (Maertens
et al., 2003), thereby serving a major role
in determining the highly distinctive pat-
tern of lentiviral genome integrationwithin
active transcription units (Ciuffi andBush-
man, 2006). Thus, physical association of
LEDGF with MLL/menin on chromatin
may provide a molecular basis for the selective integration of
HIV-1 into actively transcribed regions since the epigenetic
mark placed by MLL is involved in maintaining chromatin in
a state conducive for transcription (Li et al., 2007). A tethering
role for LEDGF likely extends to other host proteins as well since
the chromosomal association of JPO2, aMyc-interacting protein
with transforming activity, is also strictly dependent on LEDGF
(Maertens et al., 2006). It remains to be determined whether
these various interactions, which target the IBD of LEDGF, are
mutually exclusive with MLL/menin and what their implications
may be for antilentiviral therapy.
The association of LEDGF with chromatinized DNA is critically
dependent on its PWWP domain (Botbol et al., 2008). This highly
conserved motif is present in a variety of chromatin-associated
proteins involved in transcriptional regulation, DNA repair, and
methylation (Stec et al., 2000). It has structural similarities with
Tudor, chromo, and MBT domains, all of which are implicated
in binding methylated lysine residues on histones (Maurer-Stroh
et al., 2003; Li et al., 2007). Structural similarities with the ligand-
binding cavities of these evolutionally related domains strongly
suggest that the PWWP domain binds to a currently undefined
component of chromatin, although a possible role in nonspecific
DNA binding has been suggested as well (Lukasik et al., 2006;
Nameki et al., 2005; Sue et al., 2004; Qiu et al., 2002). Compelling
evidence for the role of LEDGF in targeting the MLL/menin HMT
complex to chromatin is provided by the grafting of its PWWP
onto the MLL oncoprotein, which was fully capable of bypassing
the requirement for menin in oncogenesis, Hox gene misregula-
tion, and chromatin association. This artificial construct is struc-
turally similar to the Arabidopsis thaliana homologs of MLL (ATX1
and ATX2) (Alvarez-Venegas and Avramova, 2001), which con-
tain PWWP domains in their amino-terminal portions, providing
evolutionary support for the functional link between MLL and
LEDGF.
Our study indicates significant roles for LEDGF in menin-de-
pendent growth control. Menin has been reported to potentiallyCancer Cell 14, 36–46, July 2008 ª2008 Elsevier Inc. 43
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Menin Tethers MLL Proteins to LEDGF in Oncogenesisinteract with DNA (La et al., 2004) and several other proteins
(Balogh et al., 2006); however, our data suggest that menin’s
sole role in MLL leukemia is to recruit LEDGF. Our observation
that some MEN1-associated mutations specifically disrupt
LEDGF binding and compromise MLL-dependent transcription
also implicates LEDGF in MEN1 tumorigenesis. Accumulating
evidence indicates that the physiologic growth responses of en-
docrine lineage cells are heavily dependent on the MLL/menin
pathway through regulated expression of CDKIs (Franklin
et al., 1998; Milne et al., 2005; Karnik et al., 2005, 2007). In con-
trast to ATX proteins, the interaction of MLLwith LEDGF critically
mediated by menin is noncovalent, which provides a potential
mechanism for regulating their conditional association. LEDGF
is induced upon cellular stress stimuli including serum starvation
(Huang et al., 2007) and, interestingly, is secreted from and reen-
ters lens epithelial cells by penetrating the plasma membrane
(Singh et al., 1999). Thus, it is tempting to speculate that cell-
autonomous or nonautonomous induction of LEDGF may be
implicated in the growth control of endocrine and other lineages,
perhaps as part of a molecular switch for targeting of the MLL/
menin HMT complex to chromatin (Figure 7).
Our results provide a broader context for conceptualizing the
various pathologies associated with LEDGF and its binding part-
ners, which appear to be frequently targeted in diverse diseases.
In addition to making essential contributions to MLL-mediated
leukemias and endocrine tumorigenesis, LEDGF itself is targeted
by chromosomal translocations in leukemia that result in its fusion
with the nucleoporin NUP98 (Ahuja et al., 2000). The molecular
mechanism by which NUP98-LEDGF causes leukemia is un-
known; however, our data show that it is capable of associating
with MLL/menin, suggesting that it may also perturb the HOX
pathway, compatible with the more frequent fusion of NUP98
with HOX proteins themselves in leukemias. Increased LEDGF
expression is also a feature of some cancers including acute
myeloid leukemia and tumors of breast and bladder origins (Dau-
gaard et al., 2007; Huang et al., 2007), whereas autoantibodies to
LEDGF are frequently present in patients with atopic dermatitis
and other autoimmune disorders (Ganapathy and Casiano,
2004). The specific roles of MLL/menin in these various diseases
merit further investigation, as they may have important implica-
tions for therapeutic interventions in cancer, autoimmunity, and
AIDS.
EXPERIMENTAL PROCEDURES
Cell Culture and Animal Use
HB1119, ML-2, REH, and U937 cells were cultured in RPMI 1640medium sup-
plemented with 15% fetal calf serum and nonessential amino acids. 293T,
HeLa, and plat-E cells (Morita et al., 2000) were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 15% fetal calf serum and
nonessential amino acids. All experiments on mice in this study were
performed with the approval of and in accordance with the Stanford University
Administrative Panel on Laboratory Animal Care.
Vector Construction
The pCMV5 FLAG-MLL-ENL vector (Ayton et al., 2004) and pMSCV-neo con-
structs encoding MLL-ENL andMLL-AF10 (Ayton and Cleary, 2003; DiMartino
et al., 2002) were described previously. Expression vectors for various MLL
mutants were generated by restriction enzyme digestion and PCR-based mu-
tagenesis. The cDNA for menin was provided by Dr. F. Hosoda. A series of me-
nin mutants tagged with HA were generated by PCR-mediated mutagenesis44 Cancer Cell 14, 36–46, July 2008 ª2008 Elsevier Inc.and cloned into pcDNA3.1/hygro (Invitrogen) or pMSCV-hygro (Clontech).
The expression vector for LEDGF was purchased from OriGene Technologies,
Inc. The cDNA fragments for p75 and p52 were generated by PCR and cloned
into pCMV6. cDNA of Myc-tagged NUP98-LEDGF was generated by PCR
using the pMSCV NUP98-HOX9 (Iwasaki et al., 2005) and pCMV6 LEDGF
vectors as templates and subsequently cloned into the pcDNA4/HisMax vec-
tor (Invitrogen). The shRNA expression vectors were purchased from Open
Biosystems (TRCN0000012113 for Ledgf#1; TRCN0000012114 for Ledgf#2;
TRCN000034394 for Men1).
One-Step Immunopurification and Identification
of MLL/Menin-Associated Proteins
Preparation of nuclear extracts and large-scale immunoprecipitations were
performed as described elsewhere (Yokoyama et al., 2004). 293T cells were
cultured in ten 175 cm2 dishes and transfected with pCMV FLAG-MLL-ENL
and pcDNA3.1 menin-HA vectors using Lipofectamine 2000 (Invitrogen). Nu-
clear extracts were prepared from the cells 48 hr after transfection, cleared
by ultracentrifugation, and then immunoprecipitated with anti-FLAG M2 aga-
rose beads for 4 hr. After extensive washing, the purified material was sub-
jected to SDS-PAGE analysis and visualized by Coomassie brilliant blue
staining. Gel bands containing proteins of interest were subjected to mass
spectrometry by the Stanford Proteomic & Integrative Research Facility.
Immunoprecipitation and Immunoblotting
Preparation of nuclear extracts, immunoprecipitation, and immunoblotting
were performed as described elsewhere (Yokoyama et al., 2004, 2005). Pri-
mary antibodies included mouse monoclonal anti-MLLN (mmN4.4) and anti-
MLLC (mmC2.1) and rabbit polyclonal anti-MLLN (rpN1) as described previ-
ously (Yokoyama et al., 2002). Rabbit anti-DmMyb was provided by J. Lipsick.
Goat anti-menin (C19), mouse anti-Express epitope (Omni-probe D-8), and
rabbit anti-SIN3A (K-20) antibodies were purchased from Santa Cruz Biotech-
nology, Inc. Additional primary antibodies included rabbit anti-menin (BL342)
and anti-LEDGF (BL3656) (Bethyl Laboratories, Inc.), mouse anti-LEDGF (BD
Transduction Laboratories), and mouse anti-actin (MAB 1501R) (Chemicon).
Rat anti-HA antibody (3F10) conjugated with HRP or immobilized to matrix
was purchased from Roche. Rabbit anti-FLAG (F-7425) antibody and agarose
affinity beads coupled to mouse anti-FLAG M2 or anti-Myc (9E10) monoclonal
antibody were purchased from Sigma.
Virus Production
Ecotropic retrovirus was produced using plat-E packaging cells (Morita et al.,
2000). Lentivirus was produced by cotransfection of viral vectors with pCMV
gag-pol and pVSVG env packaging constructs into 293T cells (Dull et al.,
1998). Medium containing virus was collected 48 hr posttransfection and
used for transductions.
Myeloid Progenitor Transformation Assay
Myeloid progenitor transformation assays were performed as described else-
where (Lavau et al., 1997; Yokoyama et al., 2005). Cells (CD45.1) were
harvested from the femurs of C57BL/6 orMen1 floxed (Men1floxed/) mice. Pro-
genitors (c-kit+) were enriched by immunomagnetic selection (Miltenyi Biotec),
transduced with recombinant retroviruses by spinoculation, and plated in
methylcellulose medium (M3231, StemCell Technologies, Inc.) containing
SCF, IL-3, IL-6, and GM-CSF. In vitro Cre-dependent gene inactivation was
performed as described previously (Yokoyama et al., 2005) using 0.1 nM
4-OHT to activate the Cre-ERtam protein. For secondary transductions, 105
cells were transduced with retrovirus by spinoculation, cultured in methyl-
cellulose medium overnight, and selected for drug resistance (hygromycin
750 mg/ml or puromycin 4 mg/ml) for at least 2 days.
In Vivo Leukemogenesis Assay
Transformed cells (2 3 105) from methylcellulose cultures were transplanted
intravenously into lethally irradiated C57BL/6mice (900 rads) with 23 105 syn-
geneic bone marrow cells. Moribund mice were sacrificed, and tissues were
fixed in 10% formalin and processed for hematoxylin and eosin staining. Cells
from bone marrow and spleen were subjected to cytospin preparation
followed by May-Grunwald/Giemsa staining or cultured in methylcellulose
medium for secondary transplantation.
Cancer Cell
Menin Tethers MLL Proteins to LEDGF in OncogenesisQuantitative RT-PCR
Reverse transcription and quantitative PCR were performed as described
previously using TaqMan probes for Hoxa9 (Mm00439364_m1), Men1
(Mm00484963_m1), Gapdh (Mm99999915_g1), Ledgf (Mm01259222_g1), and
b-actin (Mm00607939_m1) purchased from Applied Biosystems. Expression
levels normalized to those of b-actin orGapdhwere calculated using a standard




ChIP was performed as described previously (Weinmann and Farnham, 2002;
Yokoyama et al., 2005) using primary antibodies specific for MLLN (rpN1),
menin (BL342), LEDGF (BL3656), or histone H3 (ab1791, purchased from
Abcam). Semiquantitative or quantitative real-time PCR was performed on
the precipitated DNAs using primers and qPCR probes described in the
Supplemental Data. The values relative to input were determined using a stan-
dard curve and the relative quantitation method as described in ABI User
Bulletin #2.
Indirect Immunofluorescence
Indirect immunofluorescence was performed as described elsewhere
(Yokoyama et al., 2001) on HeLa cells transfected with expression vectors
encoding various MLL mutant proteins. The cells were fixed, incubated with
rabbit anti-MLLN antibody (rpN1), and probed with a FITC-conjugated goat
anti-rabbit IgG secondary antibody (Santa Cruz Biotechnology). Cells were
stained with DAPI (Vector Laboratories) and analyzed by confocal immunoflu-
orescence microscopy at the Stanford Cell Sciences Imaging Facility.
SUPPLEMENTAL DATA
The Supplemental Data include four figures and two tables and can be found
with this article online at http://www.cancercell.org/cgi/content/full/14/1/36/
DC1/.
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